scholarly journals Emicizumab in the Treatment of Acquired Haemophilia: A Case Report

2019 ◽  
Vol 46 (2) ◽  
pp. 121-123 ◽  
Author(s):  
Patrick Möhnle ◽  
Isabell Pekrul ◽  
Michael Spannagl ◽  
Andreas Sturm ◽  
Delila Singh ◽  
...  
Keyword(s):  
Case Report ◽  
Haemophilia A ◽  
Acquired Haemophilia

scholarly journals Acquired haemophilia A: a case report

2017 ◽  
Vol 3 ◽  
pp. 227-231
Author(s):  
Adam Stemplewski ◽  
Paulina Stemplewska ◽  
Paulina Gorzelak-Pabiś ◽  
Marlena Broncel
Keyword(s):  
Case Report ◽  
Haemophilia A ◽  
Acquired Haemophilia

Acquired haemophilia A as a secondary autoimmune disease after alemtuzumab treatment in multiple sclerosis: A case report

2019 ◽  
Vol 27 ◽  
pp. 403-405 ◽  
Author(s):  
M. Pisa ◽  
P. Della Valle ◽  
A. Coluccia ◽  
V. Martinelli ◽  
G. Comi ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Case Report ◽  
Autoimmune Disease ◽  
Haemophilia A ◽  
Acquired Haemophilia

Efficacy of therapeutic plasma exchange in a patient with coagulation inhibitors (acquired haemophilia A) – A case report

2020 ◽  
Vol 59 (4) ◽  
pp. 102809
Author(s):  
Sangeeta Kumari ◽  
Parmatma Prasad Tripathi ◽  
Ratti Ram Sharma ◽  
Rekha Hans ◽  
Divjot Singh Lamba ◽  
...  
Keyword(s):  
Case Report ◽  
Plasma Exchange ◽  
Therapeutic Plasma Exchange ◽  
Haemophilia A ◽  
Acquired Haemophilia ◽  
Coagulation Inhibitors

Chronic myelomonocytic leukaemia associated with acquired haemophilia A: case report and literature review

Haemophilia ◽  
2015 ◽  
Vol 21 (4) ◽  
pp. e341-e343 ◽  
Author(s):  
Y. Liang ◽  
R.-N. Lu ◽  
R. Wang ◽  
J.-F. Zhang ◽  
W. Su ◽  
...  
Keyword(s):  
Case Report ◽  
Literature Review ◽  
Haemophilia A ◽  
Acquired Haemophilia ◽  
Chronic Myelomonocytic Leukaemia

Rituximab in the treatment of acquired haemophilia a: a case report

2012 ◽  
Vol 19 (2) ◽  
pp. 225.1-225
Author(s):  
M.A. Fernandez de Palencia Espinosa ◽  
V. Arocas Casañ ◽  
O. García Molina ◽  
I. Concepción Martín ◽  
J. Velasco Costa ◽  
...  
Keyword(s):  
Case Report ◽  
Haemophilia A ◽  
Acquired Haemophilia

Acquired haemophilia A: a case report

2009 ◽  
Vol 5 (2) ◽  
pp. 169-171 ◽  
Author(s):  
Daniela Colomba ◽  
Domenico Di Raimondo ◽  
Luciana Marino ◽  
Rita Marrone ◽  
Giuseppe Licata
Keyword(s):  
Case Report ◽  
Haemophilia A ◽  
Acquired Haemophilia

scholarly journals Acquired haemophilia A associated with autoimmune thyroiditis: a case report

2014 ◽  
Vol 8 (1) ◽  
Author(s):  
Upul GP Pathirana ◽  
Nirmali Gunawardena ◽  
Hiranya Abeysinghe ◽  
Hannah Charlotte Copley ◽  
MG Dhammika Somarathne
Keyword(s):  
Case Report ◽  
Autoimmune Thyroiditis ◽  
Haemophilia A ◽  
Acquired Haemophilia

Clinical features and outcome of acquired haemophilia A

2010 ◽  
Vol 30 (03) ◽  
pp. 156-161 ◽  
Author(s):  
R. Gheisari ◽  
B. Bomke ◽  
T. Hoffmann ◽  
R. E. Scharf
Keyword(s):  
Respiratory Diseases ◽  
Care Center ◽  
Treatment Algorithm ◽  
Early Death ◽  
Underlying Disease ◽  
Pulmonary Sarcoidosis ◽  
Relative Increase ◽  
Laboratory Evaluation ◽  
Haemophilia A ◽  
Acquired Haemophilia

SummaryWe have performed a monocenter study on 29 consecutive patients with acquired haemophilia A who were referred for diagnosis and treatment to the Düsseldorf Haemophilia Comprehensive Care Center between March 2001 and February 2010. Patients, methods: 18 men (age: 44–86 years) and 11 women (age: 20–83 years). For laboratory evaluation, a standardized staged protocol of aPTT, FVIII : C activity and concentration, mixing studies with patient and normal plasma, and quantification of inhibitor titers (Bethesda assay) was used. Diagnostic work-up included elaborate examinations for any underlying disease. Results: In 18 (62%) of the 29 patients with acquired haemophilia A, an underlying disorder was identified, including 9 patients with respiratory diseases (31%), 7 patients with autoimmune disorders (24%), one with malignancy, and one with postpartum state, while in 11 patients (38%) acquired haemophilia A remained idiopathic. Haemotherapy of bleeding, suppression or elimination of the inhibitor, and induction of immunotolerance to endogenous FVIII:C were performed according to a treatment algorithm. Predefined clinical endpoints were control of bleeding, eradication of the inhibitor, complete or partial remission (CR, PR), relapse, or early death (≤30 days). Of the 29 patients in total, 22 individuals achieved CR (76%), three had PR, one relapsed, and three died within 30 days (one of acute myocardial infarction while on anti-haemorrhagic treatment, one of sepsis while on immunosuppression due to active acquired haemophilia A, one of lung bleeding in association with pre-existing pulmonary sarcoidosis). Conclusion: This monocenter study demonstrates that control of life-threatening bleeding, eradication of the inhibitor, and induction of tolerance to endogenous FVIII have significantly improved the clinical outcome of acquired haemophilia A. Our data also suggest a shift in underlying disorders associated with acquired haemophilia A, whereby, in comparison to published studies, a relative increase in the proportion of patients with respiratory diseases is present.

Sign in / Sign up

Export Citation Format

Share Document